TuHURA Biosciences reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company filed an Investigational New Drug (IND) application for TBS-2025 in Acute Myeloid Leukemia (AML). TuHURA has received $5.7 million to date on its Parkview credit facility, which includes $2.15 million subsequent to June 30, 2026. Cash and cash equivalents were $1.0 million at quarter-end. Research and development expenses increased to $6.6 million from $4.9 million in the prior year period. The company anticipates receiving safe-to-proceed feedback from the FDA and initiating Phase 1b/2 trials for VISTA in AML during the second half of 2026. TuHURA Biosciences is a biopharmaceutical company developing immuno-oncology therapeutics to overcome resistance to cancer immunotherapy.
